Živná Martina, Dostálová Gabriela, Barešová Veronika, Mušálková Dita, Svojšová Klára, Meiseles Doria, Kinstlinger Sara, Kuchař Ladislav, Asfaw Befekadu, Poupětová Helena, Vlášková Hana, Kmochová Tereza, Vyleťal Petr, Hartmannová Hana, Hodaňová Kateřina, Stránecký Viktor, Steiner-Mrázová Lenka, Hnízda Aleš, Živný Jan, Radina Martin, Votruba Miroslav, Sovová Jana, Trešlová Helena, Stolnaja Larisa, Reková Petra, Roblová Lenka, Honsová Eva, Rychlík Ivan, Dvela-Levitt Moran, Bleyer Anthony J, Linhart Aleš, Sikora Jakub, Kmoch Stanislav
Research Unit for Rare Diseases, Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic.
Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina.
J Am Soc Nephrol. 2025 Apr 1;36(4):628-644. doi: 10.1681/ASN.0000000535. Epub 2024 Nov 12.
The clinical significance of a number of missense variants of -galactosidase A is often ambiguous. Defective proteostasis of some missense -galactosidase A variants induced chronic endoplasmic reticulum stress and the unfolded protein response. Endoplasmic reticulum stress and the unfolded protein response may explain clinical manifestations of non-classic Fabry disease.
Classic Fabry disease is caused by mutations that result in loss of enzymatic activity of -galactosidase A, lysosomal storage of globotriaosylceramide, and a resulting multisystemic disease. In non-classic Fabry disease, patients have some preserved -galactosidase A activity and a milder disease course. Heterozygous female patients may also be affected. While Fabry disease pathogenesis has been mostly attributed to catalytic deficiency of mutated -galactosidase A, lysosomal storage, and impairment of lysosomal functions, other pathogenic factors may contribute, especially in nonclassic Fabry disease.
We characterized the genetic, clinical, biochemical, molecular, cellular, and organ pathology correlates of the p.L394P -galactosidase A variant that was identified initially in six individuals with kidney failure by the Czech national screening program for Fabry disease and by further screening in an additional 24 family members.
Clinical findings in affected male patients revealed a milder clinical course, with approximately 15% residual -galactosidase A activity with normal plasma lyso-globotriaosylceramide levels and abnormally low ratio of these values. None of the four available kidney biopsies showed lysosomal storage. Laboratory investigations documented intracellular retention of mutated -galactosidase A with resulting endoplasmic reticulum stress and the unfolded protein response, which were alleviated with BRD4780, a small molecule clearing misfolded proteins from the early secretory compartment. We observed similar findings of endoplasmic reticulum stress and unfolded protein response in five kidney biopsies with several other classic and non-classic Fabry disease missense -galactosidase A variants.
We identified defective proteostasis of mutated -galactosidase A resulting in chronic endoplasmic reticulum stress and unfolded protein response of -galactosidase A expressing cells as a contributor to Fabry disease pathogenesis.
许多α-半乳糖苷酶A错义变体的临床意义通常不明确。一些α-半乳糖苷酶A错义变体的蛋白质稳态缺陷会引发慢性内质网应激和未折叠蛋白反应。内质网应激和未折叠蛋白反应可能解释非典型法布里病的临床表现。
典型法布里病由导致α-半乳糖苷酶A酶活性丧失、溶酶体中Globotriaosylceramide蓄积以及由此引发的多系统疾病的突变引起。在非典型法布里病中,患者仍保留一些α-半乳糖苷酶A活性,病程较轻。杂合子女性患者也可能受到影响。虽然法布里病的发病机制主要归因于突变的α-半乳糖苷酶A的催化缺陷、溶酶体蓄积和溶酶体功能受损,但其他致病因素可能也起作用,尤其是在非典型法布里病中。
我们对p.L394Pα-半乳糖苷酶A变体的遗传、临床、生化、分子、细胞和器官病理学相关性进行了表征,该变体最初由捷克国家法布里病筛查项目在6例肾衰竭患者中鉴定,并在另外24名家庭成员中进一步筛查。
受影响男性患者的临床发现显示病程较轻,约有15%的残余α-半乳糖苷酶A活性,血浆溶血型Globotriaosylceramide水平正常,且这些值的比例异常低。4份可用的肾活检标本均未显示溶酶体蓄积。实验室研究记录了突变的α-半乳糖苷酶A在细胞内潴留,导致内质网应激和未折叠蛋白反应,而小分子BRD4780可缓解这种反应,BRD4780能从早期分泌区清除错误折叠的蛋白质。我们在5份肾活检标本中观察到了内质网应激和未折叠蛋白反应的类似发现,这些标本含有其他几种典型和非典型法布里病的α-半乳糖苷酶A错义变体。
我们确定突变的α-半乳糖苷酶A的蛋白质稳态缺陷会导致慢性内质网应激和表达α-半乳糖苷酶A的细胞的未折叠蛋白反应,这是法布里病发病机制的一个促成因素。